Showing 1291-1300 of 1560 results for "".
- Johnson & Johnson Vision Receives FDA Approval For Tecnis Eyhance and Tecnis Eyhance Toric II Monofocal IOLshttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-next-generation-monofocal-intraocular-lens-tecnis-eyhance-and-tecnis-eyhance-toric-ii-iols/2478822/Johnson & Johnson Vision announced that the FDA has approved the Tecnis Eyhance and Tecnis Eyhance Toric II IOLs in the United States. The first implantation of Tecnis Eyhance IOL in the US will happen in Texas next week. <
- Johnson & Johnson Vision Names Peter Menziuso New Worldwide President for Vision Carehttps://modernod.com/news/johnson-johnson-vision-announces-peter-menziuso-as-the-new-worldwide-president-for-vision-care/2478812/Johnson & Johnson Vision announced that Peter Menziuso will assume the role of Worldwide President, Vision Care, for Johnson & Johnson Vision immediately. Mr. Menziuso replaces Swami Raote, who retired at the end of 2020, after a 29-year tenure with Johnson & Johnson. Mr. Menzi
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Johnson & Johnson Vision Presents New Myopia Progression and Contact Lens Findings at American Academy of Optometry Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-presents-new-myopia-progression-and-contact-lens-findings-at-american-academy-of-optometry-annual-meeting/2478387/Johnson & Johnson Vision announced clinical data from the latest in myopia research at the American Academy of Optometry’s virtual annual meeting (Academy 2020). Investigators will also reveal findings that demonstrate how Acuvue Oasys 1-Day with Hydraluxe Technology Contact Lenses redu
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- Why Johnson & Johnson is Investing in This Niche Telehealth Startuphttps://modernod.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare